WP11 supports the implementation of personalised cancer medicine by training multiple stakeholders, including the healthcare workforce and patients. WP11 will also implement a sustainable framework for an EU-wide EQA program, targeting laboratories and hospitals involved in LB-based treatment decision making.
This task involves supporting the implementation of personalised cancer medicine through standardised advanced training pathways addressing multiple professionals, including health and non-health professionals. Comprehensive cancer centres serve as a use case, and connections with other initiatives will be developed to increase the capacity of CCCs.
This task focuses on providing accurate and accredited training on the basic elements of personalised cancer medicine to healthcare system staff in different member states, with a focus on Eastern European countries. Translation into corresponding languages is considered depending on the country.
This task involves developing a communication campaign strategy to inform patients and citizens about personalised cancer medicine. It includes a streamlined workflow for rapid development and dissemination of information and educational materials. Additionally, it focuses on empowering pediatric and adolescent and young adult cancer survivors through education.
This task involves implementing an external quality assessment program to monitor the performance of participating laboratories and ensure adherence to harmonised liquid biopsy guidelines. Objectives include:
● Implementation of a stable supply chain for artificial circulating tumour DNA reference material samples.
● Coordinate and implement an annual external quality assessment program using the framework developed in CAN.HEAL.
● Distribution and empowerment of guidelines on liquid biopsy use in molecular tumour boards developed in CAN.HEAL.
This task focuses on maintaining liquid biopsy external quality assessment beyond the joint action to achieve long-term sustainability, building on the experience from Task 11.4 and in close collaboration with the European Liquid Biopsy Society network. Objectives include: